Frances A. Tosto

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 6 papers. Top paper: “Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma”.

Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma

New England Journal of Medicine(2024)10.1056/nejmoa2401532

N/A

1.5DataRank · unranked

68 citations

Rahul Lakhotia, Stefania Pittaluga, James D. Phelan, Da Wei Huang, George W. Wright +31 more

Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myeloma

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.11.28.470260

N/A

0DataRank · unranked

1 citations

Thomas Oellerich, Ping Chen, Arnold Bolomsky, Michele Ceribelli, Björn Häupl +21 more

Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myeloma

Nature Communications(2022)10.1038/s41467-022-33142-x

N/A

0DataRank · unranked

26 citations

Arnold Bolomsky, Thomas Oellerich, Ping Chen, Michele Ceribelli, Björn Häupl +21 more

High-throughput chemogenetic drug screening reveals PKC-RhoA/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma

Cell Reports Medicine(2023)10.1016/j.xcrm.2023.101244

N/A

0DataRank · unranked

25 citations

Simone Lubrano, Michele Ceribelli, Damiano Cosimo Rigiracciolo, Robert Saddawi‐Konefka, Farhoud Faraji +18 more

Venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) in relapsed/refractory (R/R) and treatment‐naïve (TN) mantle cell lymphoma (MCL)

Hematological Oncology(2023)10.1002/hon.3164_437

N/A

0DataRank · unranked

1 citations

Rahul Lakhotia, Stefania Pittaluga, J. D. Phelan, Y. Yang, Theresa Davies‐Hill +17 more

Multi-Component, Time-Course screening to develop combination cancer therapies based on synergistic toxicity

Proceedings of the National Academy of Sciences(2024)10.1073/pnas.2413372121

N/A

0DataRank · unranked

8 citations

Frances A. Tosto, Xiaohu Zhang, Christopher Melani, Mark Roschewski, Erin Beck +13 more